Lilly back in COVID-19 antibody game with $720 million deal with U.S. for omicron-busting hopeful

Here comes Eli Lilly with yet another COVID-19 monoclonal antibody treatment. The company’s latest offering has yet to be authorized but is billed as effective against the omicron variant.

The U.S. has agreed to a $720 million deal for bebtelovimab, the company announced on Thursday. Lilly has submitted its request for an emergency use authorization, and contingent upon an FDA nod, the company will supply 600,000 courses of the treatment for high-risk patients with mild-to-moderate COVID-19.